nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—G0 and Early G1—E2F5—ocular cancer	0.041	0.0478	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—E2F4—ocular cancer	0.0402	0.0468	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—MYBL2—ocular cancer	0.0402	0.0468	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—RBL1—ocular cancer	0.0394	0.0459	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—RBL2—ocular cancer	0.0362	0.0421	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—MYBL2—ocular cancer	0.0357	0.0416	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—RBBP4—ocular cancer	0.0342	0.0398	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—CDC25A—ocular cancer	0.0325	0.0378	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—TFDP1—ocular cancer	0.0318	0.037	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—HDAC1—ocular cancer	0.0184	0.0215	CbGpPWpGaD
Dexrazoxane—Extravasation—Carboplatin—ocular cancer	0.0161	0.114	CcSEcCtD
Dexrazoxane—TOP2A—G0 and Early G1—E2F1—ocular cancer	0.0152	0.0177	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—E2F2—ocular cancer	0.0145	0.0169	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—CDK2—ocular cancer	0.0131	0.0152	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2C—ocular cancer	0.0128	0.0149	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—E2F3—ocular cancer	0.0126	0.0147	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RBBP4—ocular cancer	0.0126	0.0147	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDC25A—ocular cancer	0.012	0.014	CbGpPWpGaD
Dexrazoxane—Phlebitis—Carboplatin—ocular cancer	0.0118	0.0836	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TFDP1—ocular cancer	0.0117	0.0136	CbGpPWpGaD
Dexrazoxane—Myelosuppression—Dactinomycin—ocular cancer	0.0111	0.0786	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F5—ocular cancer	0.0106	0.0124	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND3—ocular cancer	0.0106	0.0124	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYBL2—ocular cancer	0.0104	0.0121	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F4—ocular cancer	0.0104	0.0121	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RBL1—ocular cancer	0.0102	0.0119	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F2—ocular cancer	0.0102	0.0119	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RBL2—ocular cancer	0.00939	0.0109	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CRTC1—ocular cancer	0.0093	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F3—ocular cancer	0.00886	0.0103	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RBBP4—ocular cancer	0.00886	0.0103	CbGpPWpGaD
Dexrazoxane—Febrile neutropenia—Dactinomycin—ocular cancer	0.00867	0.0612	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDC25A—ocular cancer	0.00843	0.00982	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ID2—ocular cancer	0.00829	0.00966	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TFDP1—ocular cancer	0.00824	0.0096	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK6—ocular cancer	0.00791	0.00921	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—E2F4—ocular cancer	0.0079	0.0092	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RBL1—ocular cancer	0.00774	0.00902	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND3—ocular cancer	0.00747	0.0087	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—HDAC1—ocular cancer	0.0068	0.00792	CbGpPWpGaD
Dexrazoxane—Extravasation—Dactinomycin—ocular cancer	0.00598	0.0422	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—E2F1—ocular cancer	0.0056	0.00652	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK6—ocular cancer	0.00557	0.00648	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—ocular cancer	0.00554	0.00645	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—ocular cancer	0.0054	0.00628	CbGpPWpGaD
Dexrazoxane—Infection—Carboplatin—ocular cancer	0.00498	0.0352	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—ocular cancer	0.00483	0.00562	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND2—ocular cancer	0.00479	0.00558	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—HDAC1—ocular cancer	0.00479	0.00558	CbGpPWpGaD
Dexrazoxane—Oesophagitis—Dactinomycin—ocular cancer	0.00477	0.0337	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2C—ocular cancer	0.00469	0.00546	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—ocular cancer	0.00456	0.00531	CbGpPWpGaD
Dexrazoxane—Sepsis—Dactinomycin—ocular cancer	0.00453	0.032	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—ocular cancer	0.00443	0.00516	CbGpPWpGaD
Dexrazoxane—Phlebitis—Dactinomycin—ocular cancer	0.00439	0.031	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2B—ocular cancer	0.00429	0.005	CbGpPWpGaD
Dexrazoxane—Pain—Carboplatin—ocular cancer	0.00429	0.0303	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2C—ocular cancer	0.00419	0.00488	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—GNA11—ocular cancer	0.00415	0.00484	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—ocular cancer	0.00397	0.00462	CbGpPWpGaD
Dexrazoxane—Body temperature increased—Carboplatin—ocular cancer	0.00396	0.028	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F1—ocular cancer	0.00394	0.00459	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F5—ocular cancer	0.0039	0.00455	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—GNAQ—ocular cancer	0.00386	0.0045	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F4—ocular cancer	0.00382	0.00445	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYBL2—ocular cancer	0.00382	0.00445	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RBL1—ocular cancer	0.00375	0.00437	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F2—ocular cancer	0.00375	0.00437	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—E2F5—ocular cancer	0.00349	0.00406	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—HDAC1—ocular cancer	0.00348	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RBL2—ocular cancer	0.00344	0.00401	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—E2F4—ocular cancer	0.00342	0.00398	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYBL2—ocular cancer	0.00342	0.00398	CbGpPWpGaD
Dexrazoxane—Aspartate aminotransferase increased—Dactinomycin—ocular cancer	0.00341	0.0241	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK2—ocular cancer	0.0034	0.00396	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—ocular cancer	0.00338	0.00394	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—E2F2—ocular cancer	0.00335	0.00391	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RBL1—ocular cancer	0.00335	0.00391	CbGpPWpGaD
Dexrazoxane—Dysphagia—Dactinomycin—ocular cancer	0.00327	0.0231	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RBBP4—ocular cancer	0.00325	0.00379	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F3—ocular cancer	0.00325	0.00379	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00325	0.00379	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—ocular cancer	0.00321	0.00374	CbGpPWpGaD
Dexrazoxane—Pancytopenia—Dactinomycin—ocular cancer	0.00311	0.0219	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDC25A—ocular cancer	0.00309	0.0036	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—ocular cancer	0.00309	0.0036	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RBL2—ocular cancer	0.00308	0.00359	CbGpPWpGaD
Dexrazoxane—Neutropenia—Dactinomycin—ocular cancer	0.00306	0.0216	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TFDP1—ocular cancer	0.00302	0.00352	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00298	0.00348	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—ocular cancer	0.00295	0.00343	CbGpPWpGaD
Dexrazoxane—Pneumonia—Dactinomycin—ocular cancer	0.00293	0.0207	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RBBP4—ocular cancer	0.00291	0.00339	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—E2F3—ocular cancer	0.00291	0.00339	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—ocular cancer	0.00285	0.00332	CbGpPWpGaD
Dexrazoxane—Stomatitis—Dactinomycin—ocular cancer	0.00284	0.0201	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—ocular cancer	0.00279	0.00325	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDC25A—ocular cancer	0.00276	0.00322	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND3—ocular cancer	0.00274	0.00319	CbGpPWpGaD
Dexrazoxane—Agranulocytosis—Dactinomycin—ocular cancer	0.00272	0.0192	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—TFDP1—ocular cancer	0.0027	0.00315	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.00257	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND3—ocular cancer	0.00245	0.00285	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.00243	0.00283	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—ocular cancer	0.00236	0.00275	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—ocular cancer	0.00233	0.00272	CbGpPWpGaD
Dexrazoxane—Alopecia—Dactinomycin—ocular cancer	0.00231	0.0163	CcSEcCtD
Dexrazoxane—Erythema—Dactinomycin—ocular cancer	0.00228	0.0161	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—ocular cancer	0.00217	0.00253	CbGpPWpGaD
Dexrazoxane—Ill-defined disorder—Dactinomycin—ocular cancer	0.00212	0.0149	CcSEcCtD
Dexrazoxane—Anaemia—Dactinomycin—ocular cancer	0.00211	0.0149	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—ocular cancer	0.00207	0.00241	CbGpPWpGaD
Dexrazoxane—Malaise—Dactinomycin—ocular cancer	0.00206	0.0145	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK6—ocular cancer	0.00204	0.00238	CbGpPWpGaD
Dexrazoxane—Leukopenia—Dactinomycin—ocular cancer	0.00204	0.0144	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—ocular cancer	0.00201	0.00234	CbGpPWpGaD
Dexrazoxane—Myalgia—Dactinomycin—ocular cancer	0.00194	0.0137	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—ocular cancer	0.00194	0.00226	CbGpPWpGaD
Dexrazoxane—Discomfort—Dactinomycin—ocular cancer	0.00192	0.0135	CcSEcCtD
Dexrazoxane—Infection—Dactinomycin—ocular cancer	0.00185	0.0131	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK6—ocular cancer	0.00183	0.00213	CbGpPWpGaD
Dexrazoxane—Thrombocytopenia—Dactinomycin—ocular cancer	0.00182	0.0129	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.0018	0.0021	CbGpPWpGaD
Dexrazoxane—Anorexia—Dactinomycin—ocular cancer	0.00177	0.0125	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HDAC1—ocular cancer	0.00176	0.00204	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND2—ocular cancer	0.00176	0.00204	CbGpPWpGaD
Dexrazoxane—Musculoskeletal discomfort—Dactinomycin—ocular cancer	0.0017	0.012	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—ocular cancer	0.00166	0.00194	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.00165	0.00192	CbGpPWpGaD
Dexrazoxane—Decreased appetite—Dactinomycin—ocular cancer	0.00162	0.0114	CcSEcCtD
Dexrazoxane—Fatigue—Dactinomycin—ocular cancer	0.0016	0.0113	CcSEcCtD
Dexrazoxane—Pain—Dactinomycin—ocular cancer	0.00159	0.0112	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2B—ocular cancer	0.00157	0.00183	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.00157	0.00183	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—HDAC1—ocular cancer	0.00157	0.00183	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND2—ocular cancer	0.00157	0.00183	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Dactinomycin—ocular cancer	0.00153	0.0108	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Dactinomycin—ocular cancer	0.00152	0.0107	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.00152	0.00177	CbGpPWpGaD
Dexrazoxane—Body temperature increased—Dactinomycin—ocular cancer	0.00147	0.0104	CcSEcCtD
Dexrazoxane—Abdominal pain—Dactinomycin—ocular cancer	0.00147	0.0104	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.00145	0.00168	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F1—ocular cancer	0.00144	0.00168	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2B—ocular cancer	0.00141	0.00164	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EP300—ocular cancer	0.00139	0.00162	CbGpPWpGaD
Dexrazoxane—Asthenia—Dactinomycin—ocular cancer	0.00134	0.00943	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—E2F1—ocular cancer	0.00129	0.0015	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Dactinomycin—ocular cancer	0.00127	0.00899	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.00126	0.00147	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.00126	0.00146	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK2—ocular cancer	0.00125	0.00145	CbGpPWpGaD
Dexrazoxane—Vomiting—Dactinomycin—ocular cancer	0.00118	0.00836	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—ocular cancer	0.00118	0.00137	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK2—ocular cancer	0.00111	0.0013	CbGpPWpGaD
Dexrazoxane—Nausea—Dactinomycin—ocular cancer	0.00111	0.00781	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—ocular cancer	0.00105	0.00123	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.00103	0.00121	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—ocular cancer	0.00102	0.00119	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—ocular cancer	0.000993	0.00116	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RB1—ocular cancer	0.000915	0.00107	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000874	0.00102	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—ocular cancer	0.000797	0.000928	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—ocular cancer	0.00078	0.000909	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—ocular cancer	0.00076	0.000886	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—ocular cancer	0.000735	0.000857	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—ocular cancer	0.000713	0.00083	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—EP300—ocular cancer	0.0007	0.000815	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—ocular cancer	0.00068	0.000792	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—ocular cancer	0.000658	0.000766	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—EP300—ocular cancer	0.000626	0.000729	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—ocular cancer	0.00061	0.00071	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—ocular cancer	0.000545	0.000635	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—ocular cancer	0.000448	0.000522	CbGpPWpGaD
